Upload
nguyenkhue
View
224
Download
0
Embed Size (px)
Citation preview
Avian Influenza (H5N1) & Pandemic Risk
Dr C M ChuMD, MSc (Lond), FRCP (Lond, Edin, Glasg), PDipID
Senior Medical OfficerDepartment of Medicine & GeriatricsUnited Christian Hospital
Influenza virus
Photo: courtesy of Dr W Lim, PHLC.Influenza virus type A, B, C (nucleoprotein)
Lipid envelope
RNA/nucleoprotein
H & N
H and N subtypes of influenza A isolated in animals and human
Host of origin
Humans Pigs Horses Birds*
Haemagglutinin H1/1934/PR H1 H3 H1subtypes H2/1957/Sing H3 H7(H1 - H16) H3/1968/HK
H5/1997/HK H16H7/2003/NLH9/1999/HK
Neuraminidase N1/1934/PR N1 N7 N1subtypes N2/1957/Sing N2 N8(N1 - N9) N3/2004/Can
N7/2003/NL N9
* Highly pathogenic H5 and H7 - outbreaks in poultry.
Pandemic potential
1889 1918 1957 1968 1977 1997 20031999 2005
0.5M 0.07M 0.03M 6/18 0/2 H7N3 0/2
H7N7 1/89
H5N1 60/117H1N1 H2N2 H3N2H1N1 H5N1
1900
H9N2?
H3N8
?H2N?H3N?
Excessdeath (US)
Historical timeline of influenza pandemic and recent avian influenza activity in human
Seroepidemiology ???aviangenesequence
H2, N2,PB1genes fromavian virus
H3, PB1genes fromavian virus
H1N1 ?LeakagefromRussianlab
Poultry to human transmission
Pandemic influenza: overall estimated attack rate 10-20% and mortality rate 1.3%.
Human to human transmission
Chen H, et al. PNAS 2006
H NPGD
Vietnam
Hunan
Yunan
Indonesia
Chen H, et al. PNAS 2006
H5N1 surveillance in birds of southern China (2002–2005)
H5N1 non-H5N1
(H3, 6, 9, 11)
Migratory birds
n=13115 6 (0.34%) 38 (2%)
Market poultry
n=51121 512 (1%) 3051 (6%)
HA sublineages
1. Guangdong, Hong Kong (GD)
2. Vietnam, Thailand, Malaysia (VTM)
3. Hunan, Yunnan, Indonesia (HN, YN, IDN)
To Europe
? migratory birds
? poultry trafficking
H5N1 in poultry and wild birds
?
Migratory birds
Local wild birds
Backyard farms or farms with poor biosecurity and erratic vaccination
Environment: farms, homes, markets, transport, contaminated by virus
Proposed model for control of bird flu
?
90% of H5N1 isolates are from ducks and geese
0
5
10
15
20
25
30
35
40
45
H5N
1 is
olat
es (%
)
Goose Duck chicken Minorpoultry
Yen et al., J Infect Dis 2005
a Virus titres in eggs (log10EID50/mL), MDCK cells (log10PFU/mL), and mice (log10mouse 50% LD/mL).b Number of infectious units (EID50 and PFU) in one MLD50.
Higher viral load Higher infectivity
H5N1 infection
Clinical feature
In 20032 isolated human cases of H5N1 infections (imported)1 person died subsequently
Farm chicken outbreak(Mar/Apr)
Farm / market chicken outbreak(Oct/Nov)
Culling (1.5 M)
Table 1. Impact of avian influenza on human and birds in the HKSAR.
033.835 millions720Total
0112 (imported)2003
0.919 million2002
1.372 million2001
021999
1.544 millions6181997
Number ofmortality
Number of documented human cases
Number of Poultry affected or stamped out
Number ofmortality
Number of documentedhuman cases
Year
H9N2H5N1
H5N1 pneumonia = 13 Death = 7 (53.8%)
Clinical features of human infection by avian influenza A virus(Up to 20/10/2005)
Conj, ILICAP, ILI, diarrh, enceph
Conj, ILI, CAP
CAPILICAP, ILIConjConjInitial synd
0 (0%)67 (51.5%)1 (%)1 (50%)0 (0%)6 (33.3%)0 (0%)0 (0%)No.of cases (fatal)
2130892 (imp)21813No. of cases
H7N3H5N1H7N7H5N1H9N2H5N1H7N7H7N7Agent
AvianAvianAvianAvianAvianAvianAvianSealAnimal source
Canada2004
SE Asia, 2003to now
NL2003
HK2003
HK1999
HK1997
UK1995
USA1980
ILI: acute onset of fever, cough ± sorethroat ± myalgia
CAP: fever + new pulmonary infiltrate + respiratory symptoms (SOB, cough) withno recent hospitalization
Analysis of Clinical Features (1)ILI(7) CAP (11) p value
1. Mean age ± SD (yrs) 2.86 ± 1.35 26.3 ± 18.5 0.002(range) (1 - 5) (3 - 60)
2. M : F ratio 5 : 2 3 : 8 NS
3. Underlying illness 2 4 NS
4. Mean duration of symptoms 3.3 ± 3.3 5.0 ± 3.3 NSto admission ± SD (days)
5. Persistent fever before 3 10 < 0.05admission
6. Mean admission 38.9 ± 0.68 39.2 ± 0.81 NStemperature ± SD (°C)
7. URTI symptoms 5 10 NS8. LRTI signs 0 11 < 0.0019. GI symptoms 2 8 NS
Analysis of Clinical Features (2)
* Virological diagnosis: 16: culture +; 2: 4x rise anti-H5 nt Ab
ILI (7) CAP(11) p value10. Mean initial peripheral 11.2 ± 5.0 3.9 ± 1.9 < 0.015
WBC count ± SD (x 109/L)11. Lymphopenia 0 11 < 0.00112. ALC 2.57±1.71 0.48±0.26 < 0.0513. Raised ALT 1 10 < 0.00414. Impaired renal function 0 4 NS15. Hypoxaemia 0 10 < 0.00116. CXR changes 0 11 < 0.00117. Intensive care 0 10 < 0.00118. Ventilatory support 0 8 < 0.00419 Death 0 6 < 0.05
F/24 (D2 after onset of symptoms) D5 ICU admission
Photos courtesy of Dr Edward Ho
D11 D13
Vietnam (Feb 2004)
The WHO consultancy group
Prof K Y Yuen, HKUDr David S C Hui, CUHKDr Y K Ng, QMHDr C M Chu, UCH
Typical case: M 31 yrs, consumed dead chicken 5 days before illness (onset 3/1/04). Fever 40C, malaise, dry cough, SOB, headache for 2 days. His 2 sisters died of confirmed H5N1 2 weeks later.
5/1/04 6/1/04
6/1/04 Died 9/1/04
WBC 2.5, L=0.6
Plt 57, ALT 109, AST 322
Fortum, Amikacin
Shock
ARDS
Rapid progression to death: M/52 yrs old, poultry farm worker hx of contact with dead chicken. Fever 5 days/ dry cough, runny nose & SOB for 2 days. CPK 15820. Rx: Fortum & Amikacin.
9/2/04 Died 10/2/04
Atypical presentations of AI
Diarrhoea ( EID July, 2004)39-year-old woman presented with fever for 1 week, diarrhea, nausea, and vomiting, with no early respiratory symptoms, she later developed rapidly progressive pneumonia.
Encephalitis ( NEJM Feb, 2005)A four-year-old boy presented with severe diarrhea, followed by seizures, coma, and death. Viruses were isolated from cerebrospinal fluid, fecal, throat, and serum specimens. The patient's nine-year-old sister had died from a similar syndrome two weeks earlier. In both siblings, the clinical diagnosis was acute encephalitis. Neither patient had respiratory symptoms at presentation.
Influenza virus H5N1 nucleoprotein antigen expression in tissues of infected cats 7 days after inoculation
Rimmelzwaan et al., Am J Pathol 2006
Cats fed on virus-infected chicks, ganglioneuritis in submucosal & myentericplexi of small intestine: direct infection from lumen.
All cats excreted virus at respiratory & digestive tract.
H5N1: cytokine dys-regulation
Cheung CY et al. Lancet 2002.
PNAS 2004
Journal of Medical Virology 2001
PathogenesisMulti-organ involvementMarked up-regulation of pro-inflammatory cytokinesReactive haemophagocytosis demonstrated in some cases
Laboratory diagnosisClinical features and radiological features are non-specificEpidemiological link important
Contact with sick/dead birds/poultryInefficient human-to-human transmission
Rapid diagnosis of H5N1 (2)IF IF RT-PCR
Specimens flu A NP H5*
Culture – 0 2 ??? 0†n=145
Culture + H3N2 74 0 0n=81
Culture + H5N1 7 5 (+2) 10n=11* Mab against H5 (R Webster, St. Jude’s Children’s Hospital)† 2 specimens had nonspecific band, negative on hybridization
What specimens and tests should be analyzed?
VIRAL DETECTION on AB DETECTION on acute andTS, NPA, NPS, ETA, convalescent sera (TAT)BAL ± CSF, serum, stool(TAT)
GOLD STANDARD: viral culture 4x increase in microneutralizingon MDCK cells or chick embryo Ab titre (P3) using outbreak(>3 d) strain (3 d)
RAPID RT-PCR for H5/N1 or EIA/WB by baculovirus-expressedM gene of all subtypes (1 d) recombinant H5
Antigen detection for NP by ICmembrane EIA /immunofluorescence ofall subtypes (0.5–4 h)
Potential treatment options
PB2 - cap binding, endonuclease, 759 aa
PB1 - RNA polymerase, 757 aa
(ribavirin, ?viramidine)
PB1-F2 - mitochondrial toxin, 87 aa
(cellular apoptosis)
PA - RNA polymerase subunit / proteolysis, 716 aa
H (HA) - attachment to sialic acid receptor and membrane fusion, 560 aa
(neutralizing antibody, ? Convalescent plasma)
NP - complex with RNA genome, 498 aa
N (NA) - sialidase for viral release, 450 aa
(oseltamivir, zanamivir, ?peramivir)
M1 - structural / nuclear export of RNA, 252 aa
M2 - ion channel, 96 aa
(Amantadine, rimantadine)
NS1 - interferon antagonist, 230 aa
(???Interferon alpha-2b, beta)
NS2 (NEP) - nuclear export factor, 121 aa
Options of antivirals
?Efficay of antivirals in H5N1:No RCT data for H5N1 Rx & Px
Available Human H5N1 Animal data Cell-basedoptions data assay dataOseltamivir Case reports H5N1, mice +(75 mg po bd)Zanamivir – H5N1, mice +(oro-inh 10 mg bd)Ribavirin – B, mice +(0.5 g iv q8h)Adamantanes Case reports A, B; mice +/–(100 mg bd)Interferon alpha – – + (IC50 100X of
CoV & rhinovirus) Convalescent Ab (?) – MnAb +
Are these antivirals active in vitro?Is clinically useful [serum] achievable?
Antiviral IC50/EC50 (μg/L) Serum level afternormal doses (μg/L)
Oseltamivir 3 (S)1 200–40028 (R)1
339 (H274Y clone)1
31.24 (S)2
Zanamivir 0.27 (S)3 39–54 (17–142)299.07 (S)2
Ribavirin 2300–4300 (EC50) 17000 [500 mg iv]
Correlation between clinical efficacy and serum [drug] to IC50 /EC50 unknown.1 IC50 as determined by NA activity assays (Hanoi 2005).2 EC50 as determined by MDCK-SIAT1 and HAI assays (VN1203/2004).3 IC50 as determined by NA activity assays (VN1203/2004).
Amantadine
Anti-influenza treatment,1997 HKSAR experience
N = 18No antiviral in 8Antiviral given in10
Amantadine alone D1 (1)Amantadine alone D3 (1)Amantadine alone D4 (1)Amantadine alone D5 (1)Amantadine alone D6 (2)* died D13Amantadine alone D7 (2)** died D8 and D28Amantadine + iv ribavirin D11(1)* died D29Amantadine alone D12 (1)
OutcomeNo antiviral: 2 died (SLE [died D17] and Reye’s [died D12])Antiviral given: 4 died*
0
20
40
60
80
100
2003 2004 20052001 -2002
1997 -2001
2002 2003 2004 -2005
2003 2004 2005
30/37
54/54
68/82
0/2 0/61
27/1216/45
0/4
4/9
4/355/76
Freq
uenc
y (%
)
Vietnam Hong Kong SAR China
Ser31Asn only
Ser31Asn + Leu26Ile
0/3
1997-2002
Prevalence of amantadine-resistant mutants among H5N1 viruses isolated in Vietnam, Hong Kong, and China.
Cheung et al. J Infect Dis 2006 In press
Oseltamivir (Tamiflu®)
Location Year % Rx Mortality Commentof treated
Vietnam 2004 5/10 4/5 Significant delay of Rx
Thailand 2005 7/12 5/7 Both survivors completed 5 dof Rx. Median day of start =4.5 vs 9.5 (survived vs dead)
Vietnam 2005 10/10 8/10 No details
17/22
? Delay of antivirals in patients with ILI / CAP with Hx of contact with sick / dead birds
Treatment outcome of H5N1 infection by oseltamivir
? Under-dosing oseltamivir for the very young, diarrhoea, or shock
Kiso et al., Lancet 2005 (weight-based dosing)Children dosed 2 mg/kg bd in Japan18% H3N2 developed resistance
Other countries (unit-based dosing)≤15 kg = 30 mg bd>15-23 kg = 45 mg bd>23-40 kg = 60 mg bd>40 kg = 75 mg bd
Ribavirin in influenza B (mice)
Oseltamivir (5 mg/kg/day) and ribavirin (40 mg/kg/day) were used alone and in combination.
Ribavirin alone effective (90–100% survival of mice) when Rx started as late as 3 days after infection.
40% survival even when Rx started 4 days post-infection.
Oseltamivir only effective if started within 24 h.
Ribavirin + oseltamivir no better than ribavirin alone.
Smee DF, et al. Antivir Chem Chemother 2004;15:261-8.
Zanamivir
Can we just dissolve zanamivir in saline, esp for patients on intubation or CPAP/BIPAP?
Zanamivir 16 mg qid (as 16 mg/mL in normal saline) administered by disposable nebulizer at an airflow of 6–7 L/min for 10 min (Ison et al., AntivirTher 2003)
No data on serum/sputum drug concentrations in pneumonic patients or by nebulization???
Zanamivir (mcg/L) IC50 = 0.27 (S)EC50 = 299.07 (S)[serum] = 39–54 (17–142)[sputum] = 47–1336
Possible options and RCTs
Z + R?Z?RR
A + R?A?RS
High dose O
WHOSR
WHO + AWHOSS
StudyControlOseltamivir (O)Amantidine (A)
Copyright J Clin Pharmacol 2000
The dosage of oseltamivir used for Rx ? Neurotoxicity?
Copyright Drug Metab Disp 2002
Clinical pharmacokinetics of oseltamivir with probenicid
Can we enhance [serum] of oseltamivir in patients with no problems of the heart, kidney, fluid overload, and polypharmacyproblems?
The use of Neuraminidase inhibitor
? Pre-exposure Px with std dose oseltamivir (HCW)? Post-exposure Px of household contacts with std dose oseltamivir for incubation period? For Rx, durations = 14 dBut oseltamivir resistance
Le et al, Nature, 2005: 1 survivedde Jong et al, NEJM, 2005: 2 diedChen et al (unpublished): quasi-species and spontaneous oseltamivir-resistant mutant not uncommon
? Zanamivir Px: all HCW caring those on oseltamvirRx (?transmission of oseltamivir resistance)
D 9ETAD 8ETAUCH*F/60 (thymoma)
D 9LungD 8BALQEH*M/54 (old MI)
D 16ETAQEH*F/34 (SLE)
D 13ETAD 8 (D 9)NPATMH*F/25
D 5 (D 8)ETAYCHF/24
D 5ETAD 3NPAYCHF/19
D 6NPAD 3 (D 4)NPAPMHF/14
D 7ETAPWH*F/13
D 9NPAD 5 (D 7)NPAQMHF/5
D 6NPAYCHM/4
D 8NPAD 4ETATMHF/3
D 11NPAD 5TSPMHM/3
D 11ETAQEH*M/3 (index)
D 7NPAD 1 (D 4)ETAQMHM/2
D 2NPAQMHM/2
D 1NPATMHM/1
First -ve cultureSampleFirst (last) +ve cultureSampleHospitalGender/ Age
? Duration of antiviral Rx: viral culture positivity /conversion in clinical specimens
* Death
Serum samples from 16 H5N1 case patients were tested in a microneutralization assay by use of the A/Hong Kong/156/97 virus. Values represent the log2 mean titre of duplicate assays.
J Infect Dis 1999
? Duration of antiviral Rx: onset of Neutralizing antibody
Immunomodulators?
?Immunomodulators(IVIG, anti-TNF, steroid) for severe H5N1 disease:Experience from 1997 HKSAR (6/18).
IndicationsNonresponsive ARDS in 5. Sudden desaturation in 1*.
IVIG 1 dose, 9 g, D10 Died D12.
MP (500 mg x 1 D8) + HC (100 mg q8h D12-15) Died D17.
MP 1 g D11-12 Died D13.
MP 500 mg D22, tailing 53 d. Survived.CT: bilateral ground glass. L consolidation.
HC 200 mg q6h D20, tailing 8 d.* Died D29.
MP 500 mg x 1 D22, tailing 40 d SurvivedCT: diffuse fibrosis, cystic changes, ground glass appearance.
HLH
Rx of EBV-related HLH improves survivalVP-16 induces apoptosis & ⇓ cytokinesDexamethasone pro-apoptotic
N-acetylcysteineAnti-oxidantReduce influenza symptomsReduce influenza mortality in miceAnti-inflammatoryUsed with Zinc, vitamin E, selenium
Prevention
?
Migratory birds
Local wild birds
Environment: farms, homes, markets, transport, contaminated by virus
Proposed model for control of bird flu
?
Improvement of the biosecurity of industrial farms
Moratorium at hottest month for 2 weeks
Segregation &immunization
of ducks & geeseat industrial farms
Human-bird segregation: central slaughtering, personal hygiene
H5N2vaccine
Containing an emerging pandemic?? [Ferguson N. Nature 2005]
Expected pattern of spread of an uncontrolled
epidemicRo = 1.5
Successful containment of emergent pandemic influenza
R0=1.8 + social+5km prophylaxis + 5km quarantine
Containment failure due to single-country policy implementation
Strategies to contain an emerging pandemic [Ferguson N. Nature 2005]
Rapid identification of original case clusterRapid, sensitive case detection and delivery of treatmentEffective delivery of treatment to targeted populationSufficient stockpiles of drugPopulation cooperation with containing strategy (social distancing)International cooperation in policy development, epidemic surveillance and control strategy implementation
Vaccine development
Luke et al., Emerg Infect Dis 2006
Pandemic flu vaccine for all?
Global population: 6481 million
Manufacturing capacity: 300 million doses (trivalent)
900 million doses (monovalent)
2-dose regimen
1/5 dose for intradermal
Available doses for the world = 900 x 5/2 = 2250 million doses of H5 (~1/3 world population)
Adjuvants should improve immunogenicity
Altered HA cleavage site sequence with ↓ basic amino acids to ↓ virulence & ↑viral titre in chick embryo
Subvirion H5N1 vaccine (Haemagglutinin antigen)
90 µg IMI x 2 doses28 days apartHaemagglutination-inhibition titre > 1:40 in 58%Neutralisation antibody titre > 1:40 in 54%Adjuvant (Aluminium)?Intra-dermal injection?
Hae
mag
glut
inat
ioin
hibi
tion
Mic
ro-n
eutra
lisat
ion
Anything that can go wrong will go wrong
Murphy’s 3rd law
If there is a possibility of several things going wrong, the one that will cause the most damage will be the one to go wrong.
Murphy’s 4th law
AcknowledgementProf K Y Yuen & Department of Microbiology, HKUDr K S Chan, HOHHProf David Hui, CUHKDr S T Lai, PMHDr W C Yu, PMHDr C W Leung, PMHDr K Y Lai, QEHDr Vivian Wong, HAHO
HA?